Appendix 3B & s708 Notice
Released
Released
Announcement PDF
2 June 2015
The Manager
Company Announcements
Australian Securities Exchange Limited
Via Electronic Lodgment
Dear Sir/Madam
PHARMAUST LIMITED (ASX: PAA & PAAO) - SECONDARY TRADING NOTICE
PURSUANT TO SECTION 708A(5)(e) OF THE CORPORATIONS ACT 2001
The Company gives this notice pursuant to section 708A(5)(e) of the Corporations Act
2001 (Cth) (“Act”).
The Company has issued 184,000,000 Fully Paid Ordinary Shares (“Shares”) in the capital
of the Company pursuant to resolution two approved by shareholders on 26 May 2015 as
per the Appendix 3B lodged with the ASX today.
The Company advises that the Shares were issued without disclosure to investors under
Part 6D.2 of the Act. The Company, as at the date of this notice, has complied with:
(a)
the provisions of Chapter 2M of the Act as they apply to the Company; and
(b)
section 674 of the Act.
As at the date of this notice there is no information that is excluded information for the
purposes of sections 708A(7) and (8) of the Act.
Yours sincerely,
Sam Wright
Director & Company Secretary
PharmAust Limited
___________________________________________________________________________________________________________
PharmAust Limited ACN 094 006 023
Appendix 3B
New issue announcement
Rule 2.7, 3.10.3, 3.10.4, 3.10.5
Appendix 3B
New issue announcement,
application for quotation of additional securities
and agreement
Information or documents not available now must be given to ASX as soon as available. Information and
documents given to ASX become ASX’s property and may be made public.
Introduced 01/07/96 Origin: Appendix 5 Amended 01/07/98, 01/09/99, 01/07/00, 30/09/01, 11/03/02, 01/01/03, 24/10/05, 01/08/12
Name of entity
PHARMAUST LIMITED
ABN
35 094 006 023
We (the entity) give ASX the following information.
Part 1 - All issues
You must complete the relevant sections (attach sheets if there is not enough space).
1
+Class of +securities issued or to be
Fully Paid Ordinary Shares
issued
2
Number of +securities issued or to
be issued (if known) or maximum
number which may be issued
184,000,000
3
Principal terms of the +securities
(eg, if options, exercise price and
expiry date; if partly paid
+securities,
the
amount
outstanding and due dates for
+convertible
payment;
if
securities, the conversion price
and dates for conversion)
Fully Paid Ordinary Shares
+ See chapter 19 for defined terms.
01/08/2012
Appendix 3B Page 1
Appendix 3B
New issue announcement
4
Do the +securities rank equally in
all respects from the date of
allotment with an existing +class
of quoted +securities?
Yes
If the additional securities do not
rank equally, please state:
the date from which they do
the extent to which they
participate for the next
dividend, (in the case of a
trust, distribution) or interest
payment
the extent to which they do
not rank equally, other than
in relation to the next
dividend, distribution or
interest payment
5
Issue price or consideration
$0.00785
6
Purpose of the issue
(If issued as consideration for the
acquisition of assets, clearly
identify those assets)
Funds raised in the placement will be
primarily directed towards:
- Accelerating the completion of
Phase I/II clinical trial at the RAH
- Initiating a Phase II trial to
investigate the use of PPL-1 in
conjunction with chemotherapy
“Standard of Care” in patients with
cancer
- Fit out of new laboratory for
Epichem to enhance revenues
6a
Is the entity an +eligible entity
that has obtained security holder
approval under rule 7.1A?
Yes
If Yes, complete sections 6b – 6h
in relation to the +securities the
subject of this Appendix 3B, and
comply with section 6i
6b
The date the security holder
resolution under rule 7.1A was
passed
24 October 2014
6c
Number of +securities issued
without security holder approval
under rule 7.1
Nil
+ See chapter 19 for defined terms.
Appendix 3B Page 2
01/08/2012
Appendix 3B
New issue announcement
6d
Number of +securities issued
with security holder approval
under rule 7.1A
Nil
6e
Number of +securities issued
with security holder approval
under rule 7.3, or another
specific security holder approval
(specify date of meeting)
Nil
6f
Number of securities issued
under an exception in rule 7.2
Nil
6g
If securities issued under rule
7.1A, was issue price at least 75%
of 15 day VWAP as calculated
under rule 7.1A.3? Include the
issue date and both values.
Include the source of the VWAP
calculation.
Nil
6h
If securities were issued under
rule
7.1A
for
non-cash
consideration, state date on
which valuation of consideration
was released to ASX Market
Announcements
Nil
6i
Calculate the entity’s remaining
issue capacity under rule 7.1 and
rule 7.1A – complete Annexure 1
and release to ASX Market
Announcements
See Annexure 1
7
Dates of entering +securities into
uncertificated
holdings
or
despatch of certificates
1 June 2015
8
+class
Number and
of all
+securities
quoted on ASX
(including the securities in
section 2 if applicable)
Number
+Class
1,840,006,606
Fully Paid Ordinary
Shares
139,500,001
Listed Options Ex 2c,
Exp 31/08/15
+ See chapter 19 for defined terms.
01/08/2012
Appendix 3B Page 3
Appendix 3B
New issue announcement
Number
+Class
+class
9
Number and
of all
+securities not quoted on ASX
(including the securities in
section 2 if applicable)
10
Dividend policy (in the case of a
trust, distribution policy) on the
increased capital (interests)
The Company does not expect to pay a
dividend this period.
Part 2 - Bonus issue or pro rata issue
11
Is security
required?
approval
N/A
12
Is the issue renounceable or nonrenounceable?
N/A
13
Ratio in which the +securities will
be offered
N/A
14
+Class of +securities to which the
N/A
holder
offer relates
15
+Record
determine
N/A
16
Will holdings on different
registers (or subregisters) be
aggregated
for
calculating
entitlements?
N/A
17
Policy for deciding entitlements
in relation to fractions
N/A
18
Names of countries in which the
entity has +security holders who
will not be sent new issue
documents
N/A
date
entitlements
to
Note: Security holders must be told how their
entitlements are to be dealt with.
Cross reference: rule 7.7.
19
Closing date for receipt
acceptances or renunciations
of
N/A
+ See chapter 19 for defined terms.
Appendix 3B Page 4
01/08/2012
Appendix 3B
New issue announcement
20
Names of any underwriters
N/A
21
Amount of any underwriting fee
or commission
N/A
22
Names of any brokers to the issue
N/A
23
Fee or commission payable to the
broker to the issue
N/A
24
Amount of any handling fee
payable to brokers who lodge
acceptances or renunciations on
behalf of +security holders
N/A
25
If the issue is contingent on
+security holders’ approval, the
date of the meeting
N/A
26
Date entitlement and acceptance
form and prospectus or Product
Disclosure Statement will be sent
to persons entitled
N/A
27
If the entity has issued options,
and the terms entitle option
holders to participate on exercise,
the date on which notices will be
sent to option holders
N/A
28
Date rights trading will begin (if
applicable)
N/A
29
Date rights trading will end (if
applicable)
N/A
30
How do +security holders sell
their entitlements in full through
a broker?
N/A
31
How do +security holders sell part
of their entitlements through a
broker and accept for the
balance?
N/A
+ See chapter 19 for defined terms.
01/08/2012
Appendix 3B Page 5
Appendix 3B
New issue announcement
32
How do +security holders dispose
of their entitlements (except by
sale through a broker)?
N/A
33
+Despatch date
N/A
Part 3 - Quotation of securities
You need only complete this section if you are applying for quotation of securities
34
Type of securities
(tick one)
(a)
Securities described in Part 1
(b)
All other securities
Example: restricted securities at the end of the escrowed period, partly paid securities that become fully paid,
employee incentive share securities when restriction ends, securities issued on expiry or conversion of convertible
securities
Entities that have ticked box 34(a)
Additional securities forming a new class of securities
Tick to indicate you are providing the information or
documents
35
If the securities are equity securities, the names of the 20 largest holders of the
additional securities, and the number and percentage of additional securities
+
+
+
+
held by those holders
36
If the securities are equity securities, a distribution schedule of the additional
securities setting out the number of holders in the categories
+
+
+
1 - 1,000
1,001 - 5,000
5,001 - 10,000
10,001 - 100,000
100,001 and over
37
A copy of any trust deed for the additional securities
+
+ See chapter 19 for defined terms.
Appendix 3B Page 6
01/08/2012
Appendix 3B
New issue announcement
Entities that have ticked box 34(b)
38
Number of securities for which
+quotation is sought
39
Class of +securities for which
quotation is sought
40
Do the +securities rank equally in
all respects from the date of
allotment with an existing +class
of quoted +securities?
If the additional securities do not
rank equally, please state:
the date from which they do
the extent to which they
participate for the next
dividend, (in the case of a trust,
distribution)
or
interest
payment
the extent to which they do not
rank equally, other than in
relation to the next dividend,
distribution
or
interest
payment
41
Reason for request for quotation
now
Example: In the case of restricted securities, end
of restriction period
(if issued upon conversion of
another security, clearly identify
that other security)
Number
42
+Class
+class
Number and
of all
+securities
quoted on ASX
(including the securities in clause
38)
+ See chapter 19 for defined terms.
01/08/2012
Appendix 3B Page 7
Appendix 3B
New issue announcement
Quotation agreement
1
+Quotation of our additional +securities is in ASX’s absolute discretion.
ASX
may quote the +securities on any conditions it decides.
2
We warrant the following to ASX.
The issue of the +securities to be quoted complies with the law and is
not for an illegal purpose.
There is no reason why those +securities should not be granted
+quotation.
An offer of the +securities for sale within 12 months after their issue will
not require disclosure under section 707(3) or section 1012C(6) of the
Corporations Act.
Note: An entity may need to obtain appropriate warranties from subscribers for the securities in order to be able
to give this warranty
Section 724 or section 1016E of the Corporations Act does not apply to
any applications received by us in relation to any +securities to be
quoted and that no-one has any right to return any +securities to be
quoted under sections 737, 738 or 1016F of the Corporations Act at the
time that we request that the +securities be quoted.
If we are a trust, we warrant that no person has the right to return the
+securities to be quoted under section 1019B of the Corporations Act at
the time that we request that the +securities be quoted.
3
We will indemnify ASX to the fullest extent permitted by law in respect of any
claim, action or expense arising from or connected with any breach of the
warranties in this agreement.
4
We give ASX the information and documents required by this form. If any
information or document not available now, will give it to ASX before
+quotation of the +securities begins. We acknowledge that ASX is relying on
the information and documents. We warrant that they are (will be) true and
complete.
2 June 2015
Sign here: ..........................................................Date: .....................................
(Director & Company Secretary)
Sam Wright
Print name:
.........................................................
+ See chapter 19 for defined terms.
Appendix 3B Page 8
01/08/2012
Appendix 3B
New issue announcement
Appendix 3B – Annexure 1
Calculation of placement capacity under rule 7.1 and rule 7.1A
for +eligible entities
Introduced 01/08/12
Part 1
Rule 7.1 – Issues exceeding 15% of capital
Step 1: Calculate “A”, the base figure from which the placement
capacity is calculated
Insert number of fully paid ordinary
securities on issue 12 months before date
of issue or agreement to issue
1,656,006,606
Add the following:
•
Number of fully paid ordinary securities
issued in that 12 month period under
an exception in rule 7.2
•
Number of fully paid ordinary securities
issued in that 12 month period with
shareholder approval
•
184,000,000
Number of partly paid ordinary
securities that became fully paid in that
12 month period
Note:
• Include only ordinary securities here –
other classes of equity securities
cannot be added
• Include here (if applicable) the
securities the subject of the Appendix
3B to which this form is annexed
• It may be useful to set out issues of
securities on different dates as
separate line items
Subtract the number of fully paid ordinary
securities cancelled during that 12 month
period
“A”
1,840,006,606
+ See chapter 19 for defined terms.
01/08/2012
Appendix 3B Page 9
Appendix 3B
New issue announcement
Step 2: Calculate 15% of “A”
“B”
0.15
[Note: this value cannot be changed]
Multiply “A” by 0.15
276,000,991
Step 3: Calculate “C”, the amount of placement capacity under rule
7.1 that has already been used
Insert number of equity securities issued
or agreed to be issued in that 12 month
period not counting those issued:
•
Under an exception in rule 7.2
•
Under rule 7.1A
•
With security holder approval under
rule 7.1 or rule 7.4
nil
Note:
• This applies to equity securities, unless
specifically excluded – not just ordinary
securities
• Include here (if applicable ) the
securities the subject of the Appendix
3B to which this form is annexed
• It may be useful to set out issues of
securities on different dates as
separate line items
“C”
nil
Step 4: Subtract “C” from [“A” x “B”] to calculate remaining
placement capacity under rule 7.1
“A” x 0.15
276,000,991
Note: number must be same as shown in
Step 2
Subtract “C”
nil
Note: number must be same as shown in
Step 3
Total [“A” x 0.15] – “C”
276,000,991
[Note: this is the remaining placement
capacity under rule 7.1]
+ See chapter 19 for defined terms.
Appendix 3B Page 10
01/08/2012
Appendix 3B
New issue announcement
Part 2
Rule 7.1A – Additional placement capacity for eligible entities
Step 1: Calculate “A”, the base figure from which the placement
capacity is calculated
“A”
1,840,006,606
Note: number must be same as shown in
Step 1 of Part 1
Step 2: Calculate 10% of “A”
“D”
0.10
Note: this value cannot be changed
Multiply “A” by 0.10
184,000,661
Step 3: Calculate “E”, the amount of placement capacity under rule
7.1A that has already been used
Insert number of equity securities issued
or agreed to be issued in that 12 month
period under rule 7.1A
Notes:
• This applies to equity securities – not
just ordinary securities
• Include here – if applicable – the
securities the subject of the Appendix
3B to which this form is annexed
• Do not include equity securities issued
under rule 7.1 (they must be dealt with
in Part 1), or for which specific security
holder approval has been obtained
• It may be useful to set out issues of
securities on different dates as
separate line items
“E”
Nil
+ See chapter 19 for defined terms.
01/08/2012
Appendix 3B Page 11
Appendix 3B
New issue announcement
Step 4: Subtract “E” from [“A” x “D”] to calculate remaining
placement capacity under rule 7.1A
“A” x 0.10
184,000,661
Note: number must be same as shown in
Step 2
Subtract “E”
Nil
Note: number must be same as shown in
Step 3
Total [“A” x 0.10] – “E”
184,000,661
Note: this is the remaining placement
capacity under rule 7.1A
+ See chapter 19 for defined terms.
Appendix 3B Page 12
01/08/2012
Share your feedback
Discover